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Abstract
Background:  We previously described the use of tailed oligonucleotides as a means of
reprogramming alternative pre-mRNA splicing in vitro and in vivo. The tailed oligonucleotides that
were used interfere with splicing because they contain a portion complementary to sequences
immediately upstream of the target 5' splice site combined with a non-hybridizing 5' tail carrying
binding sites for the hnRNP A1/A2 proteins.
In the present study, we have tested the inhibitory activity of RNA oligonucleotides carrying
different tail structures.
Results: We show that an oligonucleotide with a 5' tail containing the human β-globin branch site
sequence inhibits the use of the 5' splice site of Bcl-xL, albeit less efficiently than a tail containing
binding sites for the hnRNP A1/A2 proteins. A branch site-containing tail positioned at the 3' end
of the oligonucleotide also elicited splicing inhibition but not as efficiently as a 5' tail. The interfering
activity of a 3' tail was improved by adding a 5' splice site sequence next to the branch site sequence.
A 3' tail carrying a Y-shaped branch structure promoted similar splicing interference. The inclusion
of branch site or 5' splice site sequences in the Y-shaped 3' tail further improved splicing inhibition.
Conclusion: Our in vitro results indicate that a variety of tail architectures can be used to elicit
splicing interference at low nanomolar concentrations, thereby broadening the scope and the
potential impact of this antisense technology.
Background
Alternative pre-messenger RNA splicing involves the dif-
ferential use of splice sites, a process that represents a
powerful and versatile way to control protein function. It
is estimated that greater than 70% of the human genes
may be alternatively spliced [1]. Striking examples high-
lighting the importance of alternative splicing are found
in many systems including programmed cell death or
apoptosis. Deregulation of apoptosis is often caused by
alterations in the alternative splicing of regulatory genes
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including cell surface receptors such as Fas; mediators
such as Bcl-2, Bcl-x and Bax; and members of the family of
caspase proteases [2,3]. Bcl-x is alternatively spliced to
produce Bcl-xL and Bcl-xS, two proteins with antagonistic
function in apoptosis [4]. In cancers and cancer cell lines,
the expression of the anti-apoptotic protein Bcl-xL is
increased and overexpression of Bcl-xL is associated with
decreased apoptosis, increased risk of metastasis, resist-
ance to chemotherapeutic drugs and poor clinical out-
come [5-9]. In contrast, the pro-apoptotic isoform Bcl-xS
can sensitize cells to chemotherapeutic agents [9-13].
Given the pivotal role that alternative splicing plays in the
diversification of protein function, strategies capable of
specifically reprogramming alternative splicing should
improve our ability to address the function of individual
isoforms, and will provide tools to alter or correct aber-
rant splicing decisions in clinically relevant genes.
Approaches that target alternative splicing can therefore
be used to modulate the expression of protein isoforms
with distinct activities. The annealing of oligonucleotides
directly complementary to splice site sequences has been
used to modulate splicing decisions of different pre-
mRNAs including tau, dystrophin and the apoptotic regu-
lator Bcl-x [reviewed in [14]]. For example, oligonucle-
otides complementary to the 5' splice site of Bcl-xL can
shift splicing toward the pro-apoptotic Bcl-xS isoform,
thereby increasing the sensitivity of the cells to chemo-
therapeutic agents [11]. Moreover, intraperitoneal injec-
tions of such oligonucleotides in mice can produce
significant changes in the splicing of a target gene in sev-
eral organs [15]. More recently, this strategy was used to
prevent the use of cryptic splice sites in mutated lamin A
transcripts responsible for Hutchinson-Gilford progeria
syndrome [16]. However, directly targeting a 5' splice site
can potentially create problems of specificity because 5'
splice site sequences conform to a consensus. Thus, an oli-
gonucleotide complementary to a selected 5' splice site
may hybridize to off-target 5' splice sites, a situation that
may compromise its effectiveness and blur the interpreta-
tion of the phenotype.
With the goal of improving the specificity and potency of
oligonucleotide-based splicing inhibition, we have devel-
oped a strategy that relies on the use of an oligonucleotide
complementary to exon sequences located immediately
upstream of the target 5' splice site. The oligonucleotide
also carries a non-hybridizing tail that contains binding
sites for the hnRNP A1/A2 proteins [17]. The protein
binding portion of the tail prevents U1 snRNP binding to
the target 5' splice site and/or compromises spliceosome
assembly. In extracts and in cells, this design inhibits
splicing at the intended site more efficiently than an oli-
gonucleotide directly targeting the 5' splice site, possibly
because of reduced hybridization to secondary sites. Such
bifunctional oligonucleotides are effective at nanomolar
concentrations in cells, and are therefore unlikely to alter
the availability of hnRNP A/B proteins which exist in
micromolar amounts in actively dividing cells. Thus, posi-
tioning hnRNP A1/A2 proteins in the vicinity of a splice
site using tailed oligonucleotides may be more specific
and can be more effective than other antisense
approaches.
Although hnRNP A1/A2 proteins are expressed in the
nucleus of actively growing mammalian cells, their abun-
dance and cellular localization vary greatly in different
mouse and human cell types [18,19]. In the present study,
we have analyzed whether bifunctional oligonucleotides
carrying a tail harboring splicing signals can interfere with
the alternative splicing of the Bcl-x pre-mRNA in vitro. We
report that a branch site can promote splicing interference
when it is part of a 5' or a 3' tail. Moreover, a branched, Y-
shaped, 3' tail also interferes with splicing. The interfering
activity of a branched tail can be further improved by
including splicing signals in the arms of the branch.
Results
Splicing interference by 5' tails in bifunctional 
oligonucleotides
We have shown previously that a bifunctional oligonucle-
otide with a 5' overhang that contains binding sites for the
hnRNP A1/A2 proteins strongly inhibits splicing when
the oligonucleotide hybridizes immediately upstream of
the 5' splice site of Bcl-xL (position -4 to -23). This block
increases the production of the alternative Bcl-xS mRNA
isoform [17]. Tails made up of poly(U) sequences or con-
taining a purine-rich sequence bound by SR proteins elic-
ited no significant splicing interference. To investigate
whether different overhangs could be active, we first
tested an oligonucleotide carrying a 21 nt-long tail that
contains the sequence of the β-globin branch site (AUAG-
GCACUGA; the underlined A representing the branch-
point) (M4B5, Fig. 6). A mammalian branch site sequence
is recognized initially by the SF1 protein and ultimately by
the U2 snRNP during spliceosome assembly [20,21]. RNA
oligonucleotides were incubated for 2 hours in a HeLa
nuclear extract containing a model ~1 Kb-long human
Bcl-x pre-mRNA transcript that contains the 5' splice sites
of Bcl-xS and Bcl-xL (Fig. 1A). Total RNA was isolated and
a RT-PCR assay was performed to measure the ratio of the
Bcl-xS and Bcl-xL amplified products. As observed previ-
ously, oligonucleotide M4, which is complementary to
positions -4 to -23 upstream of the Bcl-xL donor site but
lacks a tail, did not interfere significantly with Bcl-x splic-
ing at any of the concentrations tested (Fig. 1C and 1D).
In contrast, oligonucleotide M4A1, which contains a tail
with high-affinity binding sites for the A1/A2 proteins,
shifted splicing towards Bcl-xS with an IC50 of ~1.5 nM
(Figs. 1C and 1D). This concentration represents a ~10-BMC Biotechnology 2006, 6:5 http://www.biomedcentral.com/1472-6750/6/5
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Activity of bifunctional oligonucleotides carrying a 5' tail Figure 1
Activity of bifunctional oligonucleotides carrying a 5' tail. In vitro splicing assays using a model 964-nt long Bcl-x pre-
mRNA incubated in HeLa nuclear extracts in the presence of increasing concentrations of oligonucleotides lacking a tail (M4) 
or carrying a 5' tail (M4A1, M4A1M, M4JV2, M4BC2 and M4B5). (A) Structure of the human Bcl-x pre-mRNA. Boxes and lines 
represent exons and introns, respectively. The dashed lines indicate plasmid sequences. The position of the 5' splice sites is 
shown as well as the position of the primers used in the RT-PCR assay. The portion of the pre-mRNA targeted by hybridiza-
tion with various oligomers corresponds to nucleotide position -4 to -23, upstream of the Bcl-xL 5' splice junction. (B) Sche-
matic structure of the oligonucleotides. The horizontal portion is complementary to position -4 to -23, upstream of the Bcl-xL 
5' splice site. The presence of A1/A2 binding sites (A1BS), mutated A1/A2 binding sites (mutA1BS) or a branch site (BS) is indi-
cated. (C) The RT-PCR assay was carried out on total RNA isolated from splicing reactions performed in triplicate. The RT-
PCR products were fractionated by electrophoresis on an Agilent 2100 bioanalyser and the ratio of Bcl-xL/Bcl-xS products was 
calculated with standard deviations. The results were plotted in a graph that indicates the xL/xS ratio at various concentrations 
of oligonucleotides. (D) A computer generated image of fluorescent Bcl-x RT-PCR products is shown for the reactions per-
formed in the absence of oligonucleotide (control, lane 2) and in the presence of oligonucleotides M4, M4A1 and M4A1M at 
concentrations of 1.5, 3.0 and 6.0 nM. The position and size of the Bcl-xL and Bcl-xS products and molecular weight markers 
are indicated.
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fold excess of oligonucleotides relative to the Bcl-x pre-
mRNA. The M4A1M oligonucleotide which contains
mutations in the A1 binding sites (see Fig. 6) behaved
essentially as the tail-less M4 oligomer (Figs. 1C and 1D).
Two oligonucleotides containing different control tails of
random origins (M4JV2 and M4BC2) also lacked signifi-
cant activity even at the highest concentration tested (Fig.
6 and Fig. 1C). The oligonucleotide carrying the β-globin
branch site sequence as a 5' overhang (M4B5) displayed
inhibitory activity, but only at the highest concentration
tested (Fig. 1C). Based on this and other experiments (see
Fig. 2), the IC50 for the M4B5 oligonucleotide was esti-
mated to be in the range of 6 nM. We conclude that while
the presence of a tail is not by itself sufficient to elicit splic-
Activity of bifunctional oligonucleotides containing a 3' tail Figure 2
Activity of bifunctional oligonucleotides containing a 3' tail. The Bcl-x pre-mRNA was incubated in HeLa extracts in 
the presence of increasing amounts of oligonucleotides (panel A, BS indicating the presence of a branch site sequence in the 
tail). Each mixture was tested in triplicate. (B) RT-PCR analysis of splicing mixtures. The ratio of the Bcl-xL and Bcl-xS products 
was plotted for different concentrations of oligomers. (C) Profiles obtained on the Agilent 2100 bioanalyzer are shown for a 
control mixture (lane 2) and mixtures incubated with the M4, M4B5 and M4B3+ oligonucleotides at concentrations of 18.75, 
37.5 and 75 nM.
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ing interference, a 5' tail containing a branch site can be
interfering. Its lower efficiency compared to a tail carrying
binding sites for hnRNP A1/A2 proteins may be a charac-
teristic of the tail or may be due to differences in the sta-
bility of the oligos. To obtain some assessment of stability,
we individually incubated 5' end-labeled oligonucle-
otides with a similarly labeled control oligonucleotide
(B3+) for 0, 30 and 60 minutes in a HeLa extract under
splicing conditions. Following incubation, the mixtures
were fractionated on gels and the oligonucleotides were
quantitated to obtain a stability index for each oligonucle-
otide. Although 5' end dephosphorylation without degra-
Activity of bifunctional oligonucleotides with branched 3' tails Figure 3
Activity of bifunctional oligonucleotides with branched 3' tails. The Bcl-x pre-mRNA was incubated for 2 hours in 
HeLa extracts in the presence of increasing amounts of oligonucleotides. (A) Schematic structure of the oligonucleotides. The 
presence in the tail of a branch site (BS) or a 5' splice site (5'ss) is indicated. (B) RT-PCR analysis of splicing mixtures were set 
up in triplicate. The Bcl-xL/Bcl-xS ratio of amplified products was plotted in the graph relative to the concentration of the oli-
gonucleotides. (C) The profile obtained on the Agilent 2100 bioanalyzer is shown for selected mixtures including a control 
mixture (lane 2) and mixtures containing oligonucleotides M4, M4-25D and M4-25C at 1.5, 3.0, 6.0 and 7.5 nM. The position 
and size of the Bcl-x amplified products are shown, as well as the size of molecular weight markers.
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dation will lead to an overestimation of the instability of
the oligonucleotides, the assay nevertheless allows the
establishment of apparent stability indices that may be
useful to a first approximation. Based on this assay (Fig.
5), we conclude that M4A1 and M4A1M display compara-
ble stabilities. M4B5 and M4BC2 also have similar stabil-
ities but are less stable than M4A1, a situation that may
explain why M4B5 is less efficient than M4A1. In contrast,
the control M4JV2 appears as the least stable oligonucle-
otide.
A 3' tail also displays interfering activity
An oligonucleotide carrying a 5' tail bound by hnRNP A1/
A2 interferes with splicing in two ways: first, it reduces U1
snRNP binding to the 5' splice site, and second, it inter-
feres with later steps of spliceosome assembly [17].
Because a spliceosome occupies ~25 nt on either side of
the 5' splice junction [21], we asked whether a tail emerg-
ing 24 nt upstream of the 5' splice junction would be
interfering. Thus, we compared the interfering activity of
M4B5 with that of an oligonucleotide carrying the β-
globin branch site sequence as part of a 3' tail (M4B3; Fig.
6). As can be seen in Fig. 2B, the interfering activity of
M4B3 was approximately 7 times inferior to that of M4B5
(IC50 of 45 nM for M4B3), despite the fact that the M4B3
appears more stable than M4B5 (Fig. 5). Thus, a branch
site tail positioned at the 3' end of a bifunctional oligonu-
cleotide is not as active as a similar tail located at the 5'
end.
To try to improve the interfering activity of the 3' tail, we
generated oligonucleotide M4B3+, which contains a 5'
splice site next to the branch site sequence in the tail of
oligonucleotide M4B3 (Fig. 6). The interfering activity of
M4B3+ was now indistinguishable from that of M4B5
(Figs. 2B and 2C). It is possible that this 7-fold improve-
ment in activity is in part due to the superior stability of
the M4B3+ oligo (a 2.5-fold difference relative to M4B3;
see Fig. 5). U1 snRNP binding to the oligonucleotide may
provide protection against nucleases. The shift obtained
with M4B3+ requires that the tail be linked to the M4 por-
tion of the oligonucleotide since adding a free tail (B3+)
to the splicing mixture did not inhibit Bcl-xL mRNA pro-
duction (Fig. 2B).
Activity of branched 3' tails
Next, we wished to assess whether splicing interference
could be improved by using an oligonucleotide that con-
tains a Y-shaped branched structure as part of the 3' tail. A
non-hybridizing branched oligonucleotide can inhibit
splicing when added at high concentration (5 µM) to a
nuclear extract [22], suggesting that the branched struc-
ture is bound by splicing factors. A low concentration of a
bifunctional oligonucleotide carrying such a branched
structure may elicit specific splicing inhibition if posi-
tioned near a 5' splice site. Oligonucleotide M4-25E con-
tains three identical 10 nt-long segments of the sequence
AAUGUCUGCU. One repeat is linked to the others via a
2'-5' bond (Fig. 6). The 10 nt repeat sequence displays no
significant interfering activity when present in a regular 5'
tail (M4BC2; Fig. 1C). Notably, incubation of M4-25E
promoted a shift toward Bcl-xS production with an IC50 of
~5 nM (Fig. 3B), a value comparable to the 6 nM obtained
with M4B5 and M4B3+ (Fig. 2). The M4-25E and M4B3+
oligos being of similar stability (Fig. 5), this result suggests
that a branched tail provides steric hindrance, possibly by
interacting with a branch-specific factor. The inclusion of
a branch site sequence at the base of the branched tail
(M4-25C, Fig. 6) improved splicing interference (Figs. 3B
and 3C; IC50 of ~2 nM). Note that this oligonucleotide
also contains slightly longer 3' arms but the sequence in
the arm is inactive (M4BC2; Fig. 1). The interfering activ-
ity of a branched tail was further improved by including a
β-globin 5' splice site in the 3' arms of the branch (M4-
25D, Fig. 6; Figs. 3B and 3C). With an IC50 of 1 nM, the
interference level of M4-25D was even slightly superior to
that of the 5' tailed oligonucleotide carrying A1/A2 bind-
ing sites (Fig. 1; IC50 of ~1.5 nM). However, the M4-25C
and M4-25D oligos have stability indices 3- to 4-times
superior to that of M4A1 (Fig. 5), thereby preventing us to
attribute equivalent efficiency based on the design alone.
An oligonucleotide with a branched tail carrying both the
branch site and the 5' splice site sequences (M4-55A, Fig.
6 and Fig. 3B) was slightly less active than M4-25D but
affected splicing in a manner equivalent to the branched
oligonucleotide carrying the branch site alone (M4-25C).
Because M4-55A was less stable than M4-25C and M4-
25D (Fig. 5), the combined presence of both branch site
and 5' splice site sequence appears to provide some addi-
tional efficacy.
Role of U1 snRNP in the activity of a 5' splice site tail
We have shown that bifunctional oligos with tails con-
taining branch site or 5' splice site sequences display
inhibitory activity when positioned near the Bcl-xL 5'
splice site. We wished to ascertain the contribution of U2
and U1 snRNP binding in the respective activity of the
branch site and 5' splice site tails. However, this evalua-
tion is complicated by the fact that U1 and U2 are essen-
tial splicing factors. Thus, inactivating or depleting U1 or
U2 snRNP should block splicing, preventing an assess-
ment of its importance for the activity of the tails. To cir-
cumvent this problem, we have tested various
concentrations of 2'-O-Me RNA complementary to the 5'
end of U1 or U2 snRNA to inactivate U1 or U2 snRNPs
[23,24]. Then, we selected a concentration of anti-U1
oligo that had a limited impact on the splicing efficiency
of the Bcl-x pre-mRNA, as measured by a conventional
splicing assay. Although the selected concentration of the
anti-U1 oligo did not affect splicing efficiency, itBMC Biotechnology 2006, 6:5 http://www.biomedcentral.com/1472-6750/6/5
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improved the relative use of the 5' splice site of Bcl-xS such
that the xL/xS ratio changed from 6.3 to 2.0 (Fig. 4, lanes
1 and 2, respectively). Next, we asked whether the activity
of the interfering tails was affected when the U1 snRNP
was targeted in this manner. Notably, the interfering activ-
ity of the bifunctional oligo carrying two 5' splice sites in
a branched tail (M4-25D) was compromised when we
used the extract treated with the 2'-O-Me RNA against the
5' end of U1 snRNA. As shown in Figure 4, in the mock-
treated extract, the M4-25D oligo shifted the xL/xS ratio
from 6.3 to 2.3 and 0.7 (7.4 and 74 nM of M4-25D,
respectively; compare lane 1 with lane 3 and lane 5). In
contrast, the xL/xS ratio in the U1-compromised extract
went from 2.0 in the control mixture to 2.9 and 2.7 when
supplemented with 7.4 or 74 nM of M4-25D oligo,
respectively (compare lane 2 with lane 6 and lane 8).
Thus, M4-25D almost completely eliminated the produc-
tion of Bcl-xL lariat products in the mock-treated extract
whereas it only had a minor effect in the U1-compro-
mised extract. This result is consistent with the view that
the 5' splice site carrying tail of M4-25D is acting by
recruiting U1 snRNP. In contrast, similarly targeting U2
snRNP did not affect the activity of a branch site-contain-
ing tail (data not shown). This may be because the
remaining amount of U2 snRNP is sufficient for the activ-
ity of the tail or that another factor is responsible for the
activity of the branch site tail.
Discussion
The current study demonstrates that bifunctional oligonu-
cleotides carrying a variety of tails can efficiently repro-
gram 5' splice site selection on a model Bcl-x pre-mRNA
in vitro. A tailed oligonucleotide provides interaction sites
for factors that upon binding will sterically antagonize
splice site recognition and/or spliceosome assembly. Our
previous work demonstrated that an oligonucleotide car-
rying a 5' overhang bound by hnRNP A1/A2 proteins and
a portion complementary to the sequence immediately
upstream of the Bcl-xL 5' splice site compromised the
splicing to the Bcl-xL site and improved splicing to the
upstream Bcl-xS 5' splice site in vitro and in vivo [17].
Here, we report that a 5' tail containing a branch site
sequence also provides significant interference. It is not
clear why the branch site-containing oligonucleotide is
less active than the A1/A2-bound oligonucleotide. The
oligonucleotide may fold in a way that reduces its hybrid-
ization to the target site or compromises the binding of
factors to the branch site sequence. Alternatively, the
binding of splicing factors may be less efficient or less
obstructive than when the tail is recruiting hnRNP A1/A2
proteins. Finally, the lower stability of the branch site oli-
gonucleotide may also contribute to this difference with
the oligonucleotide containing A1/A2 binding sites.
A branch site sequence presented in a 3' tail was consider-
ably less active than when part of a 5' tail, suggesting that
the interfering potential of the tail decreases when its dis-
tance relative to the 5' splice site of Bcl-xL increases. Alter-
natively, the branch site factor may bind less efficiently in
this configuration. In addition, we have observed that a 3'
tail containing a Y-shaped branched structure can inter-
Importance of U1 snRNP in the activity of the 5' splice site- containing tail Figure 4
Importance of U1 snRNP in the activity of the 5' 
splice site-containing tail. A uniformly labeled Bcl-x pre-
mRNA was incubated for 2 hours in HeLa extracts treated 
with 0.15 µM of 2'-O-Me oligonucleotides complementary to 
the 5' end of U1 snRNA. A mock-treated extract was used as 
control. Increased amounts of the bifunctional oligonucle-
otide M4-25D were tested (7.4, 37 and 74 nM). Splicing 
products were fractionated in a 6% denaturing polyacryla-
mide gel. The position of the lariat splicing products is 
shown.
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fere with splicing. Branched structures carrying 2'-5' link-
age are recognized by factors that promote debranching
[25]. Gel-shift assays indicated that the branched tail of
oligonucleotide M4-25E was stably bound by nuclear fac-
tors, whereas no stable binding was observed with the
individual arms of the branched tail (data not shown).
Although the identity of the factor(s) that binds to the
branch in these assays remains unknown, our results indi-
cate that positioning a branch 24 nt upstream of a 5' splice
site represents a strong impediment to splicing. Finally, a
stronger splicing interference was obtained when the
branched tail included a β-globin branch site or 5' splice
site. Thus, combining a branched core with spliceosomal
factor recognition elements such as a branch site or a 5'
splice site improved splicing inhibition. A branched oligo-
nucleotide with a 5' splice site sequence in each of the 3'
extensions was the most efficient branched oligomer
tested with an IC50 of 1 nM.
Our results clearly demonstrate that antisense oligonucle-
otides containing sterically interfering overhangs can
modulate 5' splice site selection. In addition to a 5' tail
carrying binding sites for hnRNP A1/A2, tails of com-
pletely different configurations worked efficiently,
thereby providing flexibility in the choice of an interfering
tail. The hnRNP A1 and A2 proteins are expressed in the
majority of transformed cells but are not abundantly
expressed in many normal human tissues [18]. Thus, tails
with binding sites for constitutively expressed factors (like
5' splice site, branch site and branch binding factors) may
be more suitable if the intention is to reprogram splicing
in normal cells.
Interfering oligonucleotides are active at low nanomolar
concentrations in vitro. We have shown that interfering
bifunctional 2'-O-Me oligonucleotides are also active in
vivo at concentrations below 50 nM [17]. Such high
potency makes them attractive alternatives to current
RNAi approaches which use short double-stranded RNAs
that, in some instances, can elicit an unwanted interferon
response [26-29]. An additional advantage relative to
RNAi-based approaches is that bifunctional oligomers can
be used to repress the production of one isoform while
simultaneously increasing the production of another iso-
form. This may be desirable when the purpose of the
intervention is to alter the ratio of spliced isoforms dis-
playing different, sometimes antagonistic activities, as is
the case with the apoptotic regulator Bcl-x.
Stability assessment of the oligos Figure 5
Stability assessment of the oligos. (A) Each oligo was 5' end-labeled with 32P and mixed with similarly labeled B3+ as an 
internal control. Following incubation in a HeLa nuclear extract for 0, 30 and 60 minutes, the labeled oligos were fractionated 
in a 12% denaturing acrylamide gel. (B) The stability indices were tabulated. The apparent stability of each oligo was determined 
from the results presented in panel A by quantitating the amounts of oligonucleotides remaining after 60 minutes of incubation, 
and normalizing for the signal of the B3+ control oligonucleotide in each sample. A stability index of 1 is obtained when an oli-
gonucleotide is as stable as B3+. A stability index greater or smaller than 1 indicates that the oligo is more or less stable than 
B3+, respectively.
AB
M4A1
M4A1M
M4B5
M4JV2
M4BC2
M4B3
M4B3+
B3+
B3+
M4-25E
M4-25C
M4-25D
M4-55A
Incubation
time
Stability
index
M4A1
M4A1M
M4B5
M4JV2
M4BC2
M4B3
M4B3+
B3+
M4-25E
M4-25C
M4-25D
M4-55A
1.09
0.84
0.44
0.22
0.40
1.23
2.95
1
2.34
3.64
3.02
2.11BMC Biotechnology 2006, 6:5 http://www.biomedcentral.com/1472-6750/6/5
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Sequence of the oligonucleotides Figure 6
Sequence of the oligonucleotides. The sequence in bold indicates complementarity to the region 4 to 23 nt upstream of the 
Bcl-xL 5' splice site. Boxed sequences contain the hnRNP A1 high-affinity binding sites UAGGGA and UAGGGU. The muta-
tions in M4A1M are underlined. The underlined sequence in M4B5, M4B3, B3, and M4-25C corresponds to a human β-globin 
branch site sequence, while the double underlined sequence represents a β-globin 5' splice site sequence.
5’ - GCCGCCGUUCUCCUGGAUCC -3 ’ M4
5’ - U A U G A U A C GCACUUACGCUGGCCGCCGUUCUCCUGGAUCCdT - 3’
5’ - UGGGUUUCUGAUAGGCACUGAGCCGCCGUUCUCCUGGAUCCdT - 3’ M4B5
5’ - UAUGAUACGCACUUACGCUGAGCCGCCGUUCUCCUGGAUCCdT - 3’ M4JV2
5’ - AAUGUCUGCUACUGGAAGAAUGCCGCCGUUCUCCUGGAUCCdT - 3’ M4BC2
5 ’- UAUGAUAGGGACUUAGGGUGGCCGCCGUUCUCCUGGAUCCdT - 3’ M4A1
M4A1M M4A1M
B3+ 5’ - AUAGGCACUGAGUUGGUAUG (L-dA) - 3’
5’ - GCCGCCGUUCUCCUGGAUCCAUAGGCACUGAGUUGGUAUG (L-dA) - 3’ M4B3+
5’ – GCCGCCGUUCUCCUGGAUCCAAUGUCUGCUAAAUGUCUGCU (L-dC) - 3’
AAUGUCUGCU (L-dC) - 3’
2’
M4 - 25E
5’ - GCCGCCGUUCUCCUGGAUCCAUAGGCACUGAAAUGUCUGCUACUGGAAGAAU (L-dC) - 3’ M4 - 25C
AAUGUCUGCUACUGGAAGAAU (L-dC) - 3’
2’
M4 – 25D 5’ - GCCGCCGUUCUCCUGGAUCCAAUGUCUGCUAGUUGGUAUGA (L-dC) - 3’
GUUGGUAUGA (L-dC) - 3’
2’
M4 – 55A 5’ - GCCGCCGUUCUCCUGGAUCCAUAGGCACUGAGUUGGUAUG (L-dA) - 3’
GUUGGUAUG (L-dA) - 3’
2’
5’ - GCCGCCGUUCUCCUGGAUCCAUAGGCACUGAAAUGUCUGCU (L-dA) - 3’ M4B3
Table I. Sequence of the oligonucleotidesBMC Biotechnology 2006, 6:5 http://www.biomedcentral.com/1472-6750/6/5
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Different strategies using tailed oligomers have recently
been described as means of reprogramming alternative
splicing decisions. Using a tail carrying binding sites for
SR proteins, Skordis and collaborators have shown that
such a tail can recapitulate the activity of an exon
enhancer element by stimulating the inclusion of exon 7
of SMN2 in vitro and in vivo [30]. Likewise, PNA-peptide
oligomers carrying 5 to 15 arginine-serine residues stimu-
lated the in vitro inclusion of two weak exons (BRCA1
exon 18 and SMN2 exon 7) [31]. In contrast to the two
preceding strategies, our approach relies on using a tail to
elicit splicing inhibition. It is possible that in all cases, the
hybridization of the oligonucleotide to exon sequences
may also repress mRNA translation, a situation that
would antagonize the impact of a splicing enhancing tail,
but would further contribute towards abrogating the
expression of a specific splice isoform when a splicing
inhibitory tail is used. For the moment however, an
increase in the arsenal of strategies that can reprogram
splicing provides greater flexibility in the choice of
approaches to alter splicing decisions in genes that affect
human diseases.
Conclusion
Alternative pre-mRNA splicing is relevant to a large variety
of human diseases including cancer. As a means of repro-
gramming splice site selection, we have used bifunctional
oligos that hybridize to exon sequences and contain a tail
designed to interfere with the use of a nearby 5' splice site.
We have tested the activity of different tail architectures
and found that tails containing a branched structure, a
branch site or a 5' splice site bound by U1 snRNP can
reprogram in vitro splicing at low nanomolar concentra-
tions. Thus, a variety of tail structures bound by different
factors may be used to reprogram 5' splice site selection.
Methods
Synthesis and purification of oligonucleotides
Linear antisense RNA oligonucleotide constructs were
synthesized on an ABI 381A DNA synthesizer using stand-
ard silyl-phosphoramidite chemistry [32]. Conversely,
branched RNAs were assembled using a well-established
convergent solid-phase methodology [33]. The conserved
adenosine branchpoint was introduced via the adenosine
bis-phosphoramidite under dilute conditions (0.03 M)
[34,35]. To afford maximal branching, high-loading CPG
was utilized [33,35]. Additionally, antisense molecules
less than 40 nucleotides in length were constructed on a
500 Å controlled-pore glass (CPG) support, whereas
longer oligonucleotides (> 40-nt) were assembled using a
1000 Å CPG pore size to prevent steric clashing between
the growing oligonucleotide strands. The antisense oligo-
nucleotides were designed to contain a 20-nucleotide por-
tion, which was complementary to the region directly
upstream (positions -4 to -23) of the Bcl-xL 5'-splice site
in the second exon of Bcl-x.
In an effort to stabilize the oligomers against exonucleases
present in HeLa extracts, dT or unnatural L-deoxynucle-
otides (L-dC and L-dA) were introduced at the 3'-termini
of the molecules (see Fig. 6) using the appropriate nucle-
oside loaded CPG [36]. Oligonucleotides were depro-
tected under standard conditions along with an ensuing
treatment with the desilylation reagent, triethylamine
hydrofluoride (TREAT-HF) to remove the 2'-tert-butyld-
imethylsilyl (TBDMS) protecting group. Furthermore, the
molecules were analyzed and purified by denaturing poly-
acrylamide gel electrophoresis (PAGE) (12% acrylamide,
7 M urea), desalted by size-exclusion chromatography
(Sephadex G-25) and their nucleotide composition con-
firmed by MALDI-TOF-MS [33]. Analysis of the oligonu-
cleotide products by denaturing PAGE revealed that all of
the compounds were synthesized with high efficiency.
Splicing and RT-PCR assays
The Bcl-x template used for in vitro transcription was
made from the pBc5/3 plasmid by PCR amplification
[37]. The PCR products were purified and the Bcl-x pre-
mRNA was synthesized using T3 RNA polymerase (USB)
in the presence of cap analog. The Bcl-x pre-mRNA con-
tained the last 331 nt of exon 2 followed by 434 nt of
intron 2 and 137 nt of exon 3. The pre-mRNA was gel-
purified as described [38] and quantified by spectro-
scopic analysis or using an Agilent 2100 bioanalyzer sta-
tion. Following the addition of the interfering
oligonucleotides in a HeLa nuclear extract [39], two
fmoles (150 pM) of the Bcl-x pre-mRNA were added and
the mixture was incubated for 2 hours under standard
splicing conditions [40]. All splicing reactions were car-
ried out in triplicate. Total RNA was extracted and puri-
fied. The reverse transcription step was performed at
37°C for 1 h using Omniscript (Qiagen) with 0.75 µM of
the bc2b primer (CGCTCTAGAACTAGTGGATC). The
reaction was followed by PCR using the following proce-
dure: 95°C for 3 min; 35 cycles at 93°C for 15 sec, 60°C
for 30 sec, 72°C for 30 sec; and a final extension at 72°C
for 3 min. Products were amplified using 0.3 µM each of
primers BX2 (TCATTTCCGACTGAAGAGTGA) and BX3
(ATGGCAGCAGTAAAGCAAGCG). The amplified prod-
ucts were fractionated and quantitated using the Agilent
2100 bioanalyzer.
For conventional splicing assays, a uniformly 32P-labeled
transcript was produced from T3 RNA polymerase tran-
scription of the PCR product derived from pBc5/3. After
incubation in HeLa extracts, the RNA products were frac-
tionated in a 6% acrylamide/7 M urea gel and the splicing
products were quantified on a PhosphorImager. Splicing
assays performed in the presence of anti-U1BMC Biotechnology 2006, 6:5 http://www.biomedcentral.com/1472-6750/6/5
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(CCUGCCAGGUAAGUA) and anti-U2 (AGAACA-
GAUACUACACUUGA) 2'-O-Me oligos contained 0.15
µM of the respective oligos.
For stability assays in nuclear extracts, oligos were 5' end
labeled with T4 polynucleotide kinase and 32P-γ-ATP. A
quantity of each oligo (8.0 nM) was incubated with equiv-
alent amounts of the B3+ oligo. Following fractionation
in a denaturing gel, the cpm values of each oligo in each
sample were counted directly using an InstantImager
(Canberra-Packard). The ratio cpm60 min/cpm0 min (nor-
malized for the intensity of the control oligo) was calcu-
lated as the stability index. Values above and below 1.0
respectively indicate a stability higher and lower than the
control B3+ oligo.
List of abbreviations
hnRNP: heterologous nuclear ribonucleoprotein particle;
PCR: polymerase chain reaction; snRNP, small nuclear
ribonucleoprotein; 2'-O-Me; 2'-O-Methyl.
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